成功取栓后动脉内辅助阿替普酶治疗急性缺血性卒中:CHOICE-2随机临床试验
CHOICE-2为西班牙14个卒中中心开展的前瞻性随机开放标签盲法终点试验,纳入440例24小时内取栓且eTICI 2b50-3的急性大血管闭塞缺血性卒中患者。取栓联合动脉内阿替普酶(0.225 mg/kg,最大20 mg,15分钟输注)组90天mRS 0-1比例为57.5%,单纯取栓组为42.5%(校正风险差15.0%,95%CI 5.7%至24.3%,P=0.002)。残余低灌注在联合组为28.6%,单纯取栓组为50.5%(校正风险差-22.0%,95%CI -31.5%至-12.4%,P<0.001);症状性颅内出血分别为1.4%与0.5%(校正OR 3.10,95%CI 0.32至30.0,P=0.33)。90天死亡率联合组12.1%,单纯取栓组6.4%(校正风险差5.9%,95%CI 0.5%至11.3%,P=0.03),作者认为死亡率升高需进一步研究。
要点
- 取栓后eTICI 2b50-3的大血管闭塞卒中患者,动脉内阿替普酶0.225 mg/kg(最大20 mg)15分钟输注使90天mRS 0-1比例提高15.0%(57.5% vs 42.5%,95%CI 5.7%至24.3%)。
- 残余低灌注在联合组28.6% vs 单纯取栓组50.5%,校正风险差-22.0%(95%CI -31.5%至-12.4%,P<0.001)。
- 症状性颅内出血联合组1.4%(3/214)vs 单纯取栓组0.5%(1/219),校正OR 3.10(95%CI 0.32至30.0,P=0.33),无统计学显著差异。
- 90天死亡率联合组12.1%(26/214)vs 单纯取栓组6.4%(14/219),校正风险差5.9%(95%CI 0.5%至11.3%,P=0.03)。
- 作者结论认为成功取栓后辅助动脉内阿替普酶增加极佳功能结局且未显著增加症状性颅内出血,但死亡率升高需进一步研究。
适用人群与场景
- 西班牙14个卒中中心、2023年12月11日至2025年11月26日纳入的急性缺血性卒中因大血管闭塞在24小时内接受取栓且达到eTICI 2b50至3的患者。
- 共3786例接受取栓,2776例(73%)符合血管造影标准,440例(12%)随机化,433例按随机分组治疗(中位年龄76岁,IQR 75-78岁;女性51%)。
诊断标准与关键阈值
- 取栓后血管造影再灌注达到eTICI 2b50至3为随机化条件。
- 主要结局为90天极佳功能结局,定义为改良Rankin量表评分0或1。
处置流程与药物剂量
- 取栓联合动脉内阿替普酶:0.225 mg/kg,最大剂量20 mg,15分钟内输注(n=221)。
- 对照为单纯取栓(n=219)。
红旗征与不能漏的情况
- 症状性颅内出血:联合组1.4%(3/214)vs 单纯取栓组0.5%(1/219),校正OR 3.10(95%CI 0.32至30.0,P=0.33)。
- 90天死亡:联合组12.1%(26/214)vs 单纯取栓组6.4%(14/219),校正风险差5.9%(95%CI 0.5%至11.3%,P=0.03)。
研究设计与关键结果
- 研究类型:随机、开放标签、盲法终点评估试验,14个卒中中心,440例随机化,433例按随机分组治疗。
- 主要终点:90天mRS 0-1在联合组57.5%(123/214)vs 单纯取栓组42.5%(93/219),校正风险差15.0%(95%CI 5.7%至24.3%,P=0.002)。
- 6个次要终点中4个无显著组间差异;残余低灌注联合组28.6%(55/192)vs 单纯取栓组50.5%(96/190),校正风险差-22.0%(95%CI -31.5%至-12.4%,P<0.001)。
- 安全性:症状性颅内出血联合组1.4%(3/214)vs 单纯取栓组0.5%(1/219),校正OR 3.10(95%CI 0.32至30.0,P=0.33);90天死亡率联合组12.1%(26/214)vs 单纯取栓组6.4%(14/219),校正风险差5.9%(95%CI 0.5%至11.3%,P=0.03)。
证据类型、等级与局限
- 证据类型:随机、开放标签、盲法终点评估临床试验。
- 作者结论:成功取栓后辅助动脉内阿替普酶增加90天极佳功能结局比例,未显著增加症状性颅内出血;联合组死亡率升高需进一步研究。
对床旁实践的改变
- 对于24小时内大血管闭塞取栓后达到eTICI 2b50-3的患者,本研究方案(动脉内阿替普酶0.225 mg/kg,最大20 mg,15分钟输注)使90天mRS 0-1比例提高15.0%,但90天死亡率升高5.9%(12.1% vs 6.4%)。
- 作者认为联合组死亡率升高需进一步研究。
指南或共识出处
- CHOICE-2随机临床试验(ClinicalTrials.gov标识符NCT05797792)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Despite high recanalization rates with endovascular thrombectomy for acute ischemic stroke due to large vessel occlusion, functional outcomes remain suboptimal. The benefit of adjunctive intra-arterial thrombolysis after successful thrombectomy is uncertain.
OBJECTIVE: To assess whether adjunctive intra-arterial alteplase after successful thrombectomy improves functional outcomes and cerebral reperfusion.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label trial with blinded outcome assessment conducted at 14 stroke centers in Spain from December 11, 2023, through November 26, 2025. A total of 440 patients with acute ischemic stroke due to large vessel occlusion treated with thrombectomy within 24 hours and achieving an expanded Treatment in Cerebral Ischemia score of 2b50 to 3 were randomized.
INTERVENTIONS: Thrombectomy plus intra-arterial alteplase (0.225 mg/kg; maximum dose, 20 mg) infused over 15 minutes (n = 221) or thrombectomy alone (n = 219).
MAIN OUTCOMES AND MEASURES: The primary outcome was an excellent functional outcome at 90 days, which was defined as a modified Rankin Scale score of 0 or 1. There were 6 secondary outcomes, including residual hypoperfusion on follow-up computed tomography perfusion. The safety outcomes included symptomatic intracranial hemorrhage and death.
RESULTS: Of 3786 patients treated with thrombectomy, 2776 (73%) fulfilled angiographic criteria and 440 (12%) were randomized. There were 433 patients who were treated as randomized (median age, 76 [IQR, 75-78] years; 51% female). At 90 days, 57.5% of patients (123/214) in the thrombectomy plus intra-arterial alteplase group had a modified Rankin Scale score of 0 or 1 vs 42.5% of patients (93/219) in the thrombectomy alone group (adjusted risk difference, 15.0% [95% CI, 5.7% to 24.3%]; P = .002). Of 6 secondary outcomes, 4 showed no significant between-group differences. Residual hypoperfusion occurred in 28.6% (55/192) of patients in the thrombectomy plus intra-arterial alteplase group vs 50.5% (96/190) of patients in the thrombectomy alone group (adjusted risk difference, -22.0% [95% CI, -31.5% to -12.4%]; P < .001) and symptomatic intracranial hemorrhage occurred in 1.4% (3/214) vs 0.5% (1/219), respectively (adjusted odds ratio, 3.10 [95% CI, 0.32 to 30.0]; P = .33). Mortality at 90 days was 12.1% (26/214) in the thrombectomy plus intra-arterial alteplase group vs 6.4% (14/219) in the thrombectomy alone group (adjusted risk difference, 5.9% [95% CI, 0.5% to 11.3%]; P = .03).
CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke and successful thrombectomy, adjunctive intra-arterial alteplase increased the proportion achieving excellent functional outcome at 90 days without a significant increase in symptomatic intracranial hemorrhage. Higher mortality in the thrombectomy plus intra-arterial alteplase group warrants further study.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05797792.
参考来源
- Renú A, Fernández-Couto MD, de la Riva P, et al. Adjunctive Intra-Arterial Alteplase After Successful Thrombectomy for Acute Ischemic Stroke: The CHOICE-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42096239. doi:10.1001/jama.2026.5164
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。